Harding BN, et al. - Using SEER-Medicare data, researchers assessed ovarian cancer-specific survival in relation to post-diagnosis use of antihypertensive (AH) medications including thiazide diuretics (TDs), angiotensin converting enzyme inhibitors (ACEIs), beta blockers (BBs) [both non-selective (NSBBs) and selective (SBBs)] and calcium channel blockers (CCBs) in this cohort study with participants including 2195 women (66+ years of age) who received a diagnosis of ovarian cancer during 2007–2012 and who survived for at least 12 months. Among women who used an ACEI, a TD, or a NSBB, lower ovarian cancer-specific mortality was evident, but no such link was present in women who received a SBB or CCB. Therefore, a relatively attenuated risk of dying from ovarian cancer was reported among women who received certain forms of an AH medication during the year after a diagnosis of ovarian cancer.